Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients


electroCore partners with UpScript to be exclusive online telehealth provider for gammaCore Sapphire CV. (Credit: Pixabay/Mian Shahzad Raza.)

electroCore, a commercial-stage bioelectronic medicine company, today announced that it has entered into exclusive agreement with UpScript, LLC in which UpScript will serve as the exclusive online telehealth provider for gammaCore Sapphire CV (nVNS). Patients can access telehealth consults for the gammaCore Sapphire CV product effective immediately by visiting or directly through

“The execution of this agreement with UpScript achieves our goal of establishing an efficient procurement process for certain known or suspected COVID-19 patients to obtain this potentially beneficial therapy under the Emergency Use Authorization (EUA) issued by the FDA,” stated Daniel Goldberger, Chief Executive Officer of electroCore. “Using UpScript’s comprehensive online telehealth platform, a patient has the ability to consult with a licensed healthcare provider in real time, and, if the therapy is deemed appropriate, have gammaCore Sapphire CV prescribed and shipped directly to his or her home.”

Pursuant to the EUA, the FDA has authorized use of the gammaCore Sapphire CV device for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider.

“At UpScript we work tirelessly to provide patients with a hassle-free way to consult with physicians and obtain therapies to improve the quality of their lives,” said Peter Ax, Chief Executive Officer of UpScript. “The availability of gammaCore Sapphire CV is an important addition to the armamentarium against the potentially devastating respiratory effects of COVID-19 infection in appropriate patients, and we are pleased that electroCore has chosen us to be their online telehealth partner for this novel therapy.”

Source: Company Press Release